Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIZ0GO)

• Drug Name: 4,17-dehydroxyriccardin C Drug Info
• Synonyms: 4,17-dehydroxyriccardin C; Riccardin C derivative, 20f; CHEMBL411912; BDBM23853

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 24860515
  TTD Drug ID: DMIZ0GO

Molecule-Related Drug Atlas

Drug(s) Targeting Oxysterols receptor LXR-beta (NR1H2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VTB-38543	DMNY3J0	Atopic dermatitis	EA80	Phase 2	[2]
2-Propanol, Isopropanol	DML5O0H	Discovery agent	N.A.	Investigative	[3]
desmosterol	DMV8SUM	Discovery agent	N.A.	Investigative	[4]
L-783483	DM6OTGE	Discovery agent	N.A.	Investigative	[5]
WAY-214950	DM8ODI7	Discovery agent	N.A.	Investigative	[6]
27-hydroxycholesterol	DM2L6OZ	Discovery agent	N.A.	Investigative	[7]
22R-hydroxycholesterol	DME8273	Discovery agent	N.A.	Investigative	[8]
GSK-9772	DM4WS3R	Discovery agent	N.A.	Investigative	[9]
Riccardin C	DM6MYGX	Discovery agent	N.A.	Investigative	[1]
2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione	DMH76SO	Discovery agent	N.A.	Investigative	[10]

Drug(s) Targeting Oxysterols receptor LXR-alpha (NR1H3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US9073931, E2	DMK9FJG	N. A.	N. A.	Patented	[11]
BDBM50177019	DMEL28G	N. A.	N. A.	Patented	[12]
US9006244, E2b	DMP0TBO	N. A.	N. A.	Patented	[13]
US9073931, E1	DM2Z43I	N. A.	N. A.	Patented	[11]
US9006244, E1	DMBF1C0	N. A.	N. A.	Patented	[13]
BDBM50177012	DM52IQF	N. A.	N. A.	Patented	[12]
US9006244, E2a	DMPDF9B	N. A.	N. A.	Patented	[13]
67S	DMJL1MB	N. A.	N. A.	Patented	[12]
US9073931, E3	DMCYM8P	N. A.	N. A.	Patented	[11]
desmosterol	DMV8SUM	Discovery agent	N.A.	Investigative	[4]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Oxysterols receptor LXR-alpha (NR1H3)	TTECBXN	NR1H3_HUMAN	Inhibitor	[1]
Oxysterols receptor LXR-beta (NR1H2)	TTXA6PH	NR1H2_HUMAN	Inhibitor	[1]

References

• [1] Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [4] Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem. 2006 Sep 22;281(38):27816-26.
• [5] A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a). Endocrinology. 2002 Jul;143(7):2548-58.
• [6] Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8.
• [7] 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem. 2001 Oct 19;276(42):38378-87.
• [8] An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996 Oct 24;383(6602):728-31.
• [9] Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. J Med Chem. 2008 Sep 25;51(18):5758-65.
• [10] Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3957-61.
• [11] Liver X receptor modulators. US9073931.
• [12] Piperazine derivatives as liver X receptor modulators. US10144715.
• [13] Liver X receptor modulators. US9006244.